Medunik presents FDA-approved hydroxyurea-based treatment for infants

Siklos® is the first and only FDA-approved hydroxyurea-based treatment indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in paediatric patients two years of age and older with sickle cell anaemia with recurrent moderate to severe painful crises.

The importance of optimal dosing of hydroxyurea in sickle cell anaemia (SCA) patients, based on patient body weight and biological and clinical response, has been well established. This is particularly relevant in paaaediatric populations, where patient weight is constantly changing.

“Medunik is proud to offer paediatric SCA patients a new option that helps optimize daily dosing. Given that the new triple-scored Siklos® 1,000 mg tablets can be divided into four equal parts of 250 mg each, when combined with the 100 mg tablets, it is now possible to adjust dosing in increments as small as 50 mg (starting at a 200 mg dose),” affirmed Dany Hallé, Vice President, Commercial Affairs, at Medunik.

Siklos 1,000mg triple-scored tablet (CNW Group/Medunik USA)

Medunik is committed to providing Siklos® at the lowest possible cost to all patients. That is why the company continues to partner with ProCare Pharmacy Care to offer cost savings and free home delivery through the Siklos At Home™ program.

For more information about prescribing Siklos® tablets, which are dissolvable in water for patients who are unable to swallow tablets whole, please visit siklosusa.com

 



 

About Medunik USA

Based in Pennsylvania, Medunik USA works to improve the health and quality of life of Americans living with rare diseases by making orphan drug therapies available in the United States. With strategic partnerships at the global level, the company has critical experience in approval and market access processes as well as the marketing of orphan drug therapies. Medunik USA makes critical medications to treat rare diseases available to American patients who might not otherwise have access to these medications. For more information, visit: www.medunikusa.com.

 

For more on hydroxyurea and its side effects, visit https://www.siklosusa.com/

Leave a Reply